ROYALTY SALE AGREEMENTRoyalty Sale Agreement • December 7th, 2006 • Orthovita Inc • Surgical & medical instruments & apparatus • New York
THIS ROYALTY SALE AGREEMENT (“Agreement”) is made and entered into as of this 5th day of December 2006, by and between Orthovita, Inc., a Pennsylvania corporation with principal offices at 77 Great Valley Parkway, Malvern, Pennsylvania 19355 (“Orthovita”), and Angiotech Pharmaceuticals (US), Inc., a Washington corporation with principal offices at 101 W. North Bend Way, Suite 201, PO Box 2840, North Bend, WA 98045 (“Angiotech”).
ContractRoyalty Sale Agreement • June 29th, 2018
• Jervois has executed a definitive agreement to sell the Nyngan and Flemington royalties to Cobalt 27 Capital Corp. for US$4.5 million; US$1.5 million in cash and US$3.0 million in Cobalt 27 common shares.
G500K Royalty Sale Agreement Signed with SilverStream SEZCRoyalty Sale Agreement • February 25th, 2020
Element 25 Limited (ASX:E25) (E25 or Company) is pleased to announce that it has entered into a binding sale and purchase agreement with SilverStream SEZC dba Vox
ROYALTY SALE AGREEMENTRoyalty Sale Agreement • November 4th, 2005 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • Georgia
This Royalty Sale Agreement (this “Agreement”) is made and entered into as of July 18, 2005 by and among Gilead Sciences, Inc., a Delaware corporation (“Gilead”), Emory University, a not-for-profit corporation organized under the laws of the State of Georgia (“Emory”), and Investors Trust & Custodial Services (Ireland) Limited, solely in its capacity as Trustee of Royalty Pharma, a unit trust organized under the laws of the Republic of Ireland (“Royalty Pharma”) (Gilead, Emory and Royalty Pharma are each a “Party” and collectively the ”Parties”).
